Additional Advances in Chemotherapy-Induced Neutropenia Research and Clinical Trials

Chemotherapy-induced neutropenia (CIN) is a common and potentially life-threatening consequence of chemotherapy, as it may lead to serious infections for patients with cancer. These infections result in hospital stays, increased morbidity and mortality, and considerable financial burden. In this interview, Dr. Maura Abbott explains the importance of managing and educating patients about CIN.  

Continue reading

Additional Advances in Chemotherapy-Induced Neutropenia Research and Clinical Trials

Chemotherapy-induced neutropenia (CIN) is a common and potentially life-threatening consequence of chemotherapy, as it may lead to serious infections for patients with cancer. These infections result in hospital stays, increased morbidity and mortality, and considerable financial burden. In this interview, Dr. Maura Abbott explains the importance of managing and educating patients about CIN.  

Continue reading

New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia With Gary Lyman, MD, MPH, and Maura Abbott, PhD, AOCNP®, CPNP

Oncology Data Advisor™ · New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia Chemotherapy-induced neutropenia (CIN) is a potentially life-threatening toxicity of chemotherapy that has been recognized as a major risk factor for the development of infections in patients with cancer (NCCN, 2021). The severity and duration of neutropenia place patients at higher risk of developing febrile neutropenia (FN) and experiencing dose reductions or delays that may comprom...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.